Seikagaku Corp (4548):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Seikagaku Corp (4548) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3433
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Seikagaku Corp (Seikagaku) is a manufacturer and supplier of pharmaceuticals and medical devices. The company offers products such as pharmaceuticals and medical devices, bulk products, endotoxin-detecting reagents and oral care products. It manufactures and markets pharmaceutical products containing hyaluronic acid. Seikagaku’s bulk products comprise hyaluronic acid and chondroitin sulfate. The company’s endotoxin-detecting reagents are used in the manufacturing process for pharmaceuticals and medical devices and water quality control of dialysis solution for artificial dialysis. The company has operations in Japan and the US. Seikagaku is headquartered in Tokyo, Japan.

Seikagaku Corp (4548) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Seikagaku Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Seikagaku Corp, Medical Devices Deals, 2012 to YTD 2018 9
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Seikagaku Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Ribomic Enters into Agreement with Seikagaku 11
Ono Pharma and Seikagaku Enter into Co-Development Agreement 12
Seikagaku Enters Into Co-Marketing Agreement With Kaken Pharma For SI-6603 13
Seikagaku Extends Distribution Agreement with Bioventus for Supartz 14
Licensing Agreements 15
Ferring Pharma Enters into Licensing Agreement with Seikagaku 15
Seikagaku Corp – Key Competitors 16
Seikagaku Corp – Key Employees 17
Seikagaku Corp – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Feb 02, 2018: SEIKAGAKU: Consolidated Financial Results for the Thrid Quarter of Fiscal year 2017 19
Feb 03, 2017: SEIKAGAKU: Consolidated Financial Results for the First Nine Months of Fiscal 2016 20
Clinical Trials 21
Sep 28, 2017: Ono and Seikagaku Announce Initiation of a Late-Stage Phase II Clinical Trial of SI-613 for Treatment of Enthesopathy 21
Jun 16, 2017: Seikagaku Initiates Phase II Study of SI-613 for Treatment of Knee Osteoarthritis in the U.S. 22
Feb 03, 2017: Seikagaku Initiates Phase III Study of SI-613 for Treatment of Osteoarthritis in Japan 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Seikagaku Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Seikagaku Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Seikagaku Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Seikagaku Corp, Medical Devices Deals, 2012 to YTD 2018 9
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ribomic Enters into Agreement with Seikagaku 11
Ono Pharma and Seikagaku Enter into Co-Development Agreement 12
Seikagaku Enters Into Co-Marketing Agreement With Kaken Pharma For SI-6603 13
Seikagaku Extends Distribution Agreement with Bioventus for Supartz 14
Ferring Pharma Enters into Licensing Agreement with Seikagaku 15
Seikagaku Corp, Key Competitors 16
Seikagaku Corp, Key Employees 17
Seikagaku Corp, Other Locations 18
Seikagaku Corp, Subsidiaries 18

List of Figures
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Seikagaku Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Seikagaku Corp, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Seikagaku Corp (4548):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SEAKR Engineering, Inc.:企業の戦略・SWOT・財務情報
    SEAKR Engineering, Inc. - Strategy, SWOT and Corporate Finance Report Summary SEAKR Engineering, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • The Bank of Kochi, Ltd.:企業の戦略・SWOT・財務情報
    The Bank of Kochi, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Bank of Kochi, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Arlington Asset Investment Corp (AI):企業の財務・戦略的SWOT分析
    Summary Arlington Asset Investment Corp (AAIC) is an investment firm that offers asset management and investment services. The firm acquires and holds mortgage-related assets. It acquires residential mortgage-backed securities issued by the US government agencies. AAIC also acquires mortgage-backed …
  • HKS Inc:企業の戦略・SWOT・財務情報
    HKS Inc - Strategy, SWOT and Corporate Finance Report Summary HKS Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Tiziana Life Sciences Plc (TILS):企業の財務・戦略的SWOT分析
    Tiziana Life Sciences Plc (TILS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • BDO International Limited:戦略・SWOT・企業財務分析
    BDO International Limited - Strategy, SWOT and Corporate Finance Report Summary BDO International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • One Way Liver SL-製薬・医療分野:企業M&A・提携分析
    Summary One Way Liver SL (OWL), formerly One Way Liver Genomics SL is a biotechnology company that discovers, develops and offers diagnostic products and metabolomics services for the healthcare sector. The company commercializes OWLiver, which is a serum based test used for steatosis and NASH diagn …
  • Getinge AB (GETI B):企業の財務・戦略的SWOT分析
    Getinge AB (GETI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Danaher Corporation (DHR)-医療機器分野:企業M&A・提携分析
    Summary Danaher Corporation (Danaher) is a medical technology company which designs, manufactures and markets medical, professional, commercial and industrial products and services. The company offers a wide range of testing instruments, communications solutions, water quality systems, medical diagn …
  • Kadant Inc. (KAI):企業の財務・戦略的SWOT分析
    Kadant Inc. (KAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Berger Paints India Ltd (BERGEPAINT):企業の財務・戦略的SWOT分析
    Berger Paints India Ltd (BERGEPAINT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • RCS MediaGroup S.p.A. (RCS):企業の財務・戦略的SWOT分析
    RCS MediaGroup S.p.A. (RCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Smiths Group Plc (SMIN):企業の財務・戦略的SWOT分析
    Smiths Group Plc (SMIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Hitachi Zosen Corporation (7004):企業の財務・戦略的SWOT分析
    Hitachi Zosen Corporation (7004) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • AEON Co Ltd (8267):企業の財務・戦略的SWOT分析
    AEON Co Ltd (8267) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Net Insight AB (NETI B):企業の財務・戦略的SWOT分析
    Net Insight AB (NETI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Unichem Laboratories Ltd (UNICHEMLAB):企業の財務・戦略的SWOT分析
    Summary Unichem Laboratories Ltd (Unichem) is an integrated, specialty pharmaceutical company which manufactures pharmaceutical formulations, generic products and active pharmaceutical ingredients (API's). The company offers its products in the therapeutic areas of gastroenterology, anti-invectives, …
  • Syntel, Inc.:戦略・SWOT・企業財務分析
    Syntel, Inc. - Strategy, SWOT and Corporate Finance Report Summary Syntel, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • University of New Mexico-製薬・医療分野:企業M&A・提携分析
    Summary University of New Mexico (UNM) is an educational service provider that offers bachelors, masters, doctoral and professional degree programs in various fields. The university offers programs such as continuing education, evening and weekend degree programs, extended learning and Latin America …
  • Genfit SA (GNFT):企業の財務・戦略的SWOT分析
    Summary Genfit SA (Genfit) is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include GFT505, NASH, TGFTX1 and Nitazoxanide (NTZ). Its TGFTX1 is a research p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆